Evaluation of a hybrid artificial liver module with liver lobule-like structure in rats with liver failure

A bioartificial liver device based on three-dimensional culture of genetically engineered hepatoma cells using hollow fibers

The bioartificial liver (BAL) device is an extracorporeal liver support system incorporating living hepatocytes. A major problem in BAL device development is to obtain a high number of functional cells. In this study, we focused on a genetically engineered mouse hepatoma cell line, Hepa/8F5, in which elevated liver functions are induced via overexpression of liver-enriched transcription factors activated by doxycycline (Dox) addition. We applied a three-dimensional culture technique using hollow fibers (HFs) to Hepa/8F5 cells. Hepa/8F5 cells responded to Dox addition by reducing their proliferative activity and performing liver-specific functions of ammonia removal and albumin secretion. The functional activities of cells depended on the timing of Dox addition. We also found that Hepa/8F5 cells in the HF culture were highly functional in a low rather than high cell density environment. We further fabricated an HF-type bioreactor with immobilized Hepa/8F5 cells as a BAL device. Although ammonia removal activity of this BAL device was lower than that of the small-scale HF bundle, albumin secretion activity was slightly higher. These results indicated that the BAL device with immobilized Hepa/8F5 cells was highly functional with potential to show curative effects in liver failure treatment.

Hepatic differentiation of mouse embryonic stem cells and induced pluripotent stem cells during organoid formation in hollow fibers

We have focused on pluripotent stem cells as a potential source of a hybrid-type artificial liver (HAL) and tried to develop a method for differentiating the pluripotent stem cells into cells of a hepatic lineage. In this study, we investigated the hepatic differentiation of mouse embryonic stem (ES) cells and induced pluripotent stem (iPS) cells by applying hollow fiber (HF)/organoid culture method, in which cultured cells form a cellular aggregate called an "organoid" in the lumen of the HF. ES and iPS cells were injected into HFs to induce organoid formation, and cells were cultured. To induce hepatic differentiation, we added differentiation-promoting agents to the culture medium. The expression levels of differentiation-related genes were up-regulated, with cell proliferation and organoid formation inside HFs. Since we were able to achieve a high cell density in culture, the maximum levels of liver-specific functions per unit volume in the differentiating ES and iPS cells reached a level comparable to or better than that of primary mouse hepatocytes. In conclusion, ES and iPS cells have the potential to be a cell source for a HAL, and the HF/organoid culture method, therefore, has promise as a basic technology for the development of a HAL.

Evaluation of a bioreactor with stacked sheet shaped organoids of primary hepatocytes

Hepatocyte organoids have an in vivo-like cell morphology and maintain cell viability and function in vitro. On the other hand, the oxygen supply to hepatocytes is sometimes limited in the core of organoids that are more than 100 mum in thickness. In this study, we designed and examined a new bioreactor using sheet-shaped organoids (organoid-sheets) in which the thickness was controlled to prevent hepatocyte death in the core of organoid due to limitation of oxygen supply. The cell culture space consisted of stacked organoid formation spaces and medium flow channels. Each space was separated by flat porous polycarbonate membranes, and the organoid thickness was controlled at 100 microm with a stainless steel spacer. Freshly isolated hepatocytes (7.0 x 10(7)) were immobilized in the bioreactor, yielding a cell density of 4.5 x 10(7) cells/cm(3)-bioreactor. Of the five flow rates tested (1.0, 5.0, 10, 20, and 50 mL/min), the bioreactor with the 10 mL/min had the highest ammonia removal and albumin secretion activities for at least 14 days. In conclusion, a new bioreactor controlling organoid thickness is useful for achieving high cell density culture and the maintenance of hepatocyte function to avoid cell death in the core of the organoids due to limitation of oxygen supply. The bioreactor may be useful for the development of various applications using cultured hepatocytes.

An overview of animal models for investigating the pathogenesis and therapeutic strategies in acute hepatic failure

Acute hepatic failure (AHF) is a severe liver injury accompanied by hepatic encephalopathy which causes multiorgan failure with an extremely high mortality rate, even if intensive care is provided. Management of severe AHF continues to be one of the most challenging problems in clinical medicine. Liver transplantation has been shown to be the most effective therapy, but the procedure is limited by shortage of donor organs. Although a number of clinical trials testing different liver assist devices are under way, these systems alone have no significant effect on patient survival and are only regarded as a useful approach to bridge patients with AHF to liver transplantation. As a result, reproducible experimental animal models resembling the clinical conditions are still needed. The three main approaches used to create an animal model for AHF are: surgical procedures, toxic liver injury and infective procedures. Most common models are based on surgical techniques (total/partial hepatectomy, complete/transient devascularization) or the use of hepatotoxic drugs (acetaminophen, galactosamine, thioacetamide, and others), and very few satisfactory viral models are available. We have recently developed a viral model of AHF by means of the inoculation of rabbits with the virus of rabbit hemorrhagic disease. This model displays biochemical and histological characteristics, and clinical features that resemble those in human AHF. In the present article an overview is given of the most widely used animal models of AHF, and their main advantages and disadvantages are reviewed.